Sen. Cassidy’s Legislative Proposal Aims to Reform the 340B Drug Pricing Program
After years of investigation, the outgoing chairman of the Senate Health, Education, Labor and Pensions Committee, Sen. Bill Cassidy, R-Louisiana, has released his opinion on new legislation to reform the controversial 340B drug pricing program. The program, designed to offer drug discounts to hospitals treating low-income or uninsured patients, has not seen a legislative update in 15 years.
Key Proposals and Industry Reactions
Sen. Cassidy introduced a discussion bill that, if enacted, would represent a significant shift in the 340B program. The bill includes measures that have sparked opposition from the hospital industry, such as allowing drug manufacturers to offer discounts or refunds following claims data submissions. This aims to address concerns of rebate duplication and diversion, alongside requiring nonprofits to regularly report their 340B revenues, costs, and eligibility.
Despite the contentious nature of some measures, the draft includes concessions addressing hospitals’ concerns. Participating providers could choose their rebate mechanisms, provided they pass on the benefits to their 340B patients, while collecting a nominal dispensing fee.
Standardization and New Definitions
Another significant aspect of the draft is the call for standardized data reporting by participating providers. This change could facilitate the adjudication of disputed information, with testing costs to be covered by either the government or drug manufacturers.
The draft also tackles long-standing ambiguities in the program. It introduces new definitions for terms like “patient” and outlines explicit guidelines for contracting pharmacies and children’s centers. Such clarifications aim to curb hospital practices that some drugmakers argue exploit legal loopholes, thus inflating margins.
Limiting Contract Pharmacies and Addressing Predatory Practices
Among the proposed changes is a limitation on the number of contract pharmacies a hospital can engage with, set at five (excluding mail-order pharmacies). This is a response to claims that some health systems have used contract pharmacies to improperly bolster revenues.
The draft also targets providers and third parties accused of “predatory practices” that skim revenue from both patients and providers. Sen. Cassidy emphasized the need for transparency and oversight to ensure 340B truly reduces costs for patients.
Stakeholder Engagement and Feedback
As of 2024, the 340B program encompasses $81 billion in drug purchases, over 16% of the nation’s total drug spending. Drugmakers argue that health systems abuse program loopholes, while hospitals contend that the discounts are crucial for sustaining care for low-income populations.
Sen. Cassidy is actively seeking feedback from stakeholders on this draft bill, viewing it as a preliminary version open for input until August 28. Maureen Testoni, president and CEO of 340B Health, which represents over 1,600 hospitals, warned that the proposals could severely limit hospitals’ ability to provide essential care.
Beth Feldpush, senior vice president of policy and advocacy at America’s Essential Hospitals, expressed her group’s willingness to collaborate with Sen. Cassidy to ensure the program supports 340B hospitals without imposing burdensome requirements.
As healthcare spending becomes a pivotal political topic, the proposal reflects a nuanced attempt to balance accountability with the financial viability of hospitals serving vulnerable communities.
Read more about the proposed reforms and their implications here.
“`
